DK4259632T3 - N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazol-5-carboxamid og n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazol-5-carboxamid-derivater som irak4-hæmmere til behandling af astma - Google Patents

N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazol-5-carboxamid og n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazol-5-carboxamid-derivater som irak4-hæmmere til behandling af astma Download PDF

Info

Publication number
DK4259632T3
DK4259632T3 DK21836097.2T DK21836097T DK4259632T3 DK 4259632 T3 DK4259632 T3 DK 4259632T3 DK 21836097 T DK21836097 T DK 21836097T DK 4259632 T3 DK4259632 T3 DK 4259632T3
Authority
DK
Denmark
Prior art keywords
indazole
cyclohexyl
carboxamide
pyridazin
pyrazolo
Prior art date
Application number
DK21836097.2T
Other languages
Danish (da)
English (en)
Inventor
Ina Terstiege
Stefan Schiesser
Yafeng Xue
Hui-Fang Chang
Anna Ingrid Kristina Berggren
Original Assignee
Astrazeneca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca filed Critical Astrazeneca
Application granted granted Critical
Publication of DK4259632T3 publication Critical patent/DK4259632T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK21836097.2T 2020-12-10 2021-12-09 N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazol-5-carboxamid og n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazol-5-carboxamid-derivater som irak4-hæmmere til behandling af astma DK4259632T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063199160P 2020-12-10 2020-12-10
PCT/EP2021/084916 WO2022122876A1 (en) 2020-12-10 2021-12-09 N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide and n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide derivatives as irak4 inhibitors for the treatment of asthma

Publications (1)

Publication Number Publication Date
DK4259632T3 true DK4259632T3 (da) 2024-10-21

Family

ID=79230946

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21836097.2T DK4259632T3 (da) 2020-12-10 2021-12-09 N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazol-5-carboxamid og n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazol-5-carboxamid-derivater som irak4-hæmmere til behandling af astma

Country Status (33)

Country Link
US (3) US11866405B2 (cg-RX-API-DMAC7.html)
EP (1) EP4259632B1 (cg-RX-API-DMAC7.html)
JP (1) JP7749015B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230118153A (cg-RX-API-DMAC7.html)
CN (1) CN116583285B (cg-RX-API-DMAC7.html)
AR (1) AR124303A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021395816B2 (cg-RX-API-DMAC7.html)
CA (1) CA3203569A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001662A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007624A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230264A (cg-RX-API-DMAC7.html)
DK (1) DK4259632T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000119A (cg-RX-API-DMAC7.html)
EC (1) ECSP23050553A (cg-RX-API-DMAC7.html)
ES (1) ES2989489T3 (cg-RX-API-DMAC7.html)
FI (1) FI4259632T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241312T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068584T2 (cg-RX-API-DMAC7.html)
IL (1) IL303356B2 (cg-RX-API-DMAC7.html)
LT (1) LT4259632T (cg-RX-API-DMAC7.html)
MA (1) MA62535B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006816A (cg-RX-API-DMAC7.html)
PE (1) PE20240684A1 (cg-RX-API-DMAC7.html)
PL (1) PL4259632T3 (cg-RX-API-DMAC7.html)
PT (1) PT4259632T (cg-RX-API-DMAC7.html)
RS (1) RS66095B1 (cg-RX-API-DMAC7.html)
SI (1) SI4259632T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400417T1 (cg-RX-API-DMAC7.html)
TW (1) TWI902994B (cg-RX-API-DMAC7.html)
UA (1) UA130417C2 (cg-RX-API-DMAC7.html)
UY (1) UY39561A (cg-RX-API-DMAC7.html)
WO (1) WO2022122876A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306848B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023152349A1 (en) * 2022-02-14 2023-08-17 Astrazeneca Ab Irak4 inhibitors
US20250326757A1 (en) * 2022-05-26 2025-10-23 Astrazeneca Ab Solid forms of heterocyclylamides as irak4 inhibitors
US20240374588A1 (en) 2023-04-07 2024-11-14 Astrazeneca Ab Irak4 protacs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体
HUE029617T2 (en) 2010-12-20 2017-03-28 Merck Serono Sa Indazolyl triazole derivatives as IRAK inhibitors
BG111378A (bg) * 2013-01-14 2015-01-30 Николай Цветков Субституирани индазолови производни като in-vitro mao-b инхибитори
RU2665554C2 (ru) * 2013-03-15 2018-08-31 Байомарин Фармасьютикал Инк. Ингибиторы hdac
HK1231480A1 (zh) 2014-01-10 2017-12-22 Aurigene Discovery Technologies Limited 作为irak4抑制剂的吲唑化合物
PL3536685T3 (pl) 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
CA2992406A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
EP3322409A4 (en) 2015-07-15 2019-07-24 Aurigene Discovery Technologies Limited SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS
CN105503863A (zh) * 2015-12-11 2016-04-20 南京华威医药科技开发有限公司 新型抗肿瘤化合物
EP3394066A2 (en) 2015-12-22 2018-10-31 H. Hoffnabb-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
US10059708B2 (en) 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
WO2017207386A1 (de) 2016-06-01 2017-12-07 Bayer Pharma Aktiengesellschaft Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen
JP2020524692A (ja) 2017-06-21 2020-08-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Irak4調節因子としてのベンゾフラン
CN110785418A (zh) 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 作为irak4调节剂的异二氢吲哚酮衍生物
KR20220027196A (ko) 2019-06-27 2022-03-07 바이오젠 엠에이 인코포레이티드 이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도
CN114585609B (zh) 2019-06-27 2024-07-30 比奥根Ma公司 2h-吲唑衍生物及其在疾病治疗中的用途

Also Published As

Publication number Publication date
UA130417C2 (uk) 2026-02-11
IL303356B1 (en) 2026-04-01
HRP20241312T1 (hr) 2024-12-20
LT4259632T (lt) 2024-10-10
EP4259632B1 (en) 2024-07-24
PE20240684A1 (es) 2024-04-10
PT4259632T (pt) 2024-10-24
CL2023001662A1 (es) 2024-01-12
JP7749015B2 (ja) 2025-10-03
KR20230118153A (ko) 2023-08-10
ES2989489T3 (es) 2024-11-26
AU2021395816B2 (en) 2024-04-04
WO2022122876A1 (en) 2022-06-16
AR124303A1 (es) 2023-03-15
US20220185817A1 (en) 2022-06-16
AU2021395816A9 (en) 2025-03-13
ZA202306848B (en) 2024-04-24
CN116583285A (zh) 2023-08-11
IL303356A (en) 2023-08-01
HUE068584T2 (hu) 2025-01-28
FI4259632T3 (fi) 2024-10-24
TW202237612A (zh) 2022-10-01
EP4259632A1 (en) 2023-10-18
UY39561A (es) 2022-06-30
US11866405B2 (en) 2024-01-09
MX2023006816A (es) 2023-06-21
RS66095B1 (sr) 2024-11-29
ECSP23050553A (es) 2023-08-31
US20240182479A1 (en) 2024-06-06
MA62535B1 (fr) 2024-11-29
CA3203569A1 (en) 2022-06-16
US20260092069A1 (en) 2026-04-02
CR20230264A (es) 2023-07-26
SI4259632T1 (sl) 2024-12-31
IL303356B2 (en) 2026-08-01
CO2023007624A2 (es) 2023-06-30
PL4259632T3 (pl) 2024-12-16
SMT202400417T1 (it) 2024-11-15
CN116583285B (zh) 2026-03-24
US12448385B2 (en) 2025-10-21
TWI902994B (zh) 2025-11-01
AU2021395816A1 (en) 2023-07-13
DOP2023000119A (es) 2023-07-09
JP2023552838A (ja) 2023-12-19

Similar Documents

Publication Publication Date Title
EP3976607A4 (en) PYRROLO[2,3-B]PYRIDINE AND PYRAZOLO[3,4-B]PYRIDINE SUBSTITUTED DERIVATIVES AS PROTEIN KINASE INHIBITORS
SI4259632T1 (sl) Derivati N-(imidazo(1,2-b)piridazin-3-il)-1-cikloheksil-2H-indazol-5- karboksamida in N-(pirazolo(1,5-a)pirimidin-3-il)-1-cikloheksil-2H- indazol-5-karboksamida kot zaviralci IRAK4 za zdravljenje astme
MY146474A (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP3684766C0 (en) NEW PROCESS FOR THE PREPARATION OF DERIVATIVES OF 7-(4,7-DIAZASPIRO[2.5]OCTAN-7-YL)-2-(2,8-DIMETHYLIMIDAZO[1,2-B]PYRIDAZIN-6-YL)PYRIDO[1,2-A]PYRIMIDIN-4-ONE.
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190144A1 (ar) إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CL2008001274A1 (es) Compuestos macrolidos derivados de 5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropan[e]pirrolo[1,2-a][1,4]diazaciclopentadecinilo, inhibidores de la actividad de la proteasa ns3-ns4; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios y procedimiento de preparacion; y uso en el tratamiento de.....
MX2019004070A (es) Sistema de extraccion de un sistema de circuito cerrado.
EP4074710A4 (en) PYRAZOLO[1,5-A]PYRIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF
IL190061A0 (en) 5-amino-4-hydroxy-7-(imidazo[1,2-a]pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
DK1812440T3 (da) Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser
CL2012001027A1 (es) Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek.
CA3266687A1 (en) PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR3 INHIBITORS FOR CANCER TREATMENT
EA201891897A1 (ru) 1,5-ДИГИДРО-4H-ПИРАЗОЛО[3,4-d]ПИРИМИДИН-4-ОНЫ И 1,5-ДИГИДРО-4H-ПИРАЗОЛО[4,3-c]ПИРИДИН-4-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1
EP3856743A4 (en) SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20200311A1 (ar) مثبطات صغيرة الجزيئات من فئة الكينازات مزدوجة الوجه (jak)
AU2024254535A1 (en) 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
IL281956A (en) History of 6,2-dimethyl-N-(pyridin-4-yl)methyl)imidazo[2,1-B]pyridazin-8-amine and 5,2-dimethyl-N-[(pyridin-4-yl)methyl] Pyrazolo[5,1-A]pyrimidine-7-amine for the treatment of viral infections
ZA200809016B (en) 4, 5-Dihydro-[1,2,4] Triazolo [4,3-F] PteridinesS as protein kinase PLK1 inhibitors for the treatment of proliferative disorders
EP4499636A4 (en) PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF TRPM3 MEDIATED DISORDERS
MX2023005761A (es) Pirrolo [2,3-b] piridina sustituida y derivados de pirazolo [3,4-b] piridina como inhibidores de proteinas quinasas.
WO2014193881A8 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
EP4436569A4 (en) POLYMORPHIC AND SALT FORMS OF (LS,3S))-N-(5-(PENTAN-3-YL)PYRAZOLO[1,5-A]PYRIMIDIN-7-YL)CYCLOPENTANE-L,3-DIAMINE